文献速递脑血管病认知障碍与痴呆

中年血浆GFAP与NfL和日后脑小血管病MRI标志物的关联

Association of Plasma GFAP and NfL in Middle-Aged Adults With MRI Markers of Cerebral Small Vessel Disease Later in Life.
PubMed 文献 · Neurology · 2025-12-29

基于英国生物银行5270名基线40-60岁参与者的回顾性分析,发现基线血浆GFAP较高与约9年后白质高信号体积、各向异性分数和平均弥散度等cSVD的MRI标志物相关,并与3年后FA和MD进展相关;NfL无显著关联。

要点

  • 中年血浆GFAP较高与日后白质高信号体积及白质微结构改变相关。
  • 基线GFAP与3年内FA和MD进展相关,提示可早期识别cSVD易感者。
  • 血浆NfL与cSVD的MRI标志物无显著关联。

核心结论

  • 中年成人血浆GFAP水平与日后白质完整性改变相关,可能作为cSVD易感性的早期指标。

研究设计与样本

  • 英国生物银行前瞻性收集数据的回顾性分析,纳入基线2006-2010年40-60岁且有血浆标志物和随访MRI(2014-2019)者,排除既往神经系统疾病,共5270人(平均54.2±7.8岁,女性53.4%)。

主要发现

  • 基线GFAP较高与9年后WMH体积(β=0.06,95%CI 0.01-0.10,p=0.014)、FA(β=0.08,95%CI 0.03-0.13,p=0.001)和MD(β=0.14,95%CI 0.09-0.18,p<0.001)相关。
  • 在1317名有纵向MRI者中,基线GFAP与3年内FA进展(β=0.012,95%CI 0.001-0.023,p=0.033)和MD进展(β=0.020,95%CI 0.003-0.038,p=0.025)相关。
  • NfL与任何MRI cSVD标志物均无显著关联。
  • 两种标志物的纵向变化与同期MRI进展无显著关联。

临床怎么用

  • 血浆GFAP或可辅助中年人群cSVD长期风险分层,支持在干预最有效的阶段早期识别高风险个体。

局限性

  • 回顾性分析设计;纵向MRI亚组样本量较小(1317人);未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Cerebral small vessel disease (cSVD) is a major contributor to stroke and dementia, often beginning decades before clinical symptoms appear. While MRI markers offer critical insight into cSVD burden, blood-based biomarkers may offer a more accessible complement to neuroimaging. We investigated whether plasma glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) are associated with MRI markers of cSVD in middle-aged adults and whether they are associated with longitudinal progression. METHODS: We conducted a retrospective analysis of prospectively collected data from the UK Biobank cohort. Participants aged 40-60 years at baseline (2006-2010) with plasma biomarker measurements and follow-up MRI scans (2014-2019) were included. Individuals with prevalent neurologic conditions were excluded. We assessed 3 MRI markers of cSVD: white matter hyperintensities (WMHs), fractional anisotropy (FA), and mean diffusivity (MD). Three analytical approaches were used: associations between baseline biomarkers and future MRI markers, associations between baseline biomarkers and longitudinal MRI changes, and correlations between longitudinal biomarker and MRI changes. Robust regression models were adjusted for age, sex, and cerebrovascular risk factors. RESULTS: Among 5,270 participants (mean age 54.2 ± 7.8 years; 53.4% female), higher baseline GFAP levels were significantly associated with all 3 MRI cSVD markers-WMH volume (β = 0.06, 95% CI 0.01-0.10, p = 0.014), FA (β = 0.08, 95% CI 0.03-0.13, p = 0.001), and MD (β = 0.14, 95% CI 0.09-0.18, p < 0.001)-after a follow-up of 9 years. Among 1,317 participants with longitudinal MRI data, baseline GFAP was associated with progression of FA (β = 0.012, 95% CI 0.001-0.023, p = 0.033) and MD (β = 0.020, 95% CI 0.003-0.038, p = 0.025) over 3 years. NfL was not significantly associated with any MRI cSVD marker. Longitudinal changes in both biomarkers showed no significant associations with concurrent MRI progression. DISCUSSION: Plasma GFAP levels were associated with subsequent changes in white matter integrity among middle-aged adults, suggesting potential utility as an early indicator of cSVD vulnerability. These associations, observed nearly a decade after biomarker measurement, highlight GFAP's potential for long-term risk stratification. Blood-based biomarkers may support earlier identification of individuals at heightened risk of cSVD, enabling preventive strategies when interventions may be most effective.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Prapiadou S, Tan BYQ, Kimball TN, et al. Association of Plasma GFAP and NfL in Middle-Aged Adults With MRI Markers of Cerebral Small Vessel Disease Later in Life. Neurology. 2025. PMID: 41461058. doi:10.1212/WNL.0000000000214481

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。